Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Status:
Completed
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the
vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with
moderate or severe ulcerative colitis (UC).